Premium
Use of recombinant factor VIIa (rFVIIa) to control intraoperative bleeding in pediatric brain tumor patients
Author(s) -
Heisel M.,
Nagib M.,
Madsen L.,
Alshiekh M.,
Bendel A.
Publication year - 2004
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20144
Subject(s) - medicine , recombinant factor viia , vascularity , dosing , factor viia , surgery , brain tumor , resection , coagulopathy , anesthesia , pathology , tissue factor , coagulation
Surgical bleeding during the resection of brain tumors in children may be related to tumor vascularity, pathology, and location. Despite improvements in neurosurgical technique, neuroanesthesia, and blood product replacement, bleeding can be life‐threatening in these surgeries. We report eight pediatric patients in whom recombinant factor VIIa (rFVIIa) was used to control intraoperative bleeding during surgical resection of pediatric brain tumors. rFVIIa should be considered as a method to control intraoperative bleeding that is unresponsive to conventional interventions. Additional studies are needed to determine optimal patient selection and drug dosing, efficacy and safety. © 2004 Wiley‐Liss, Inc.